Palmer Charles, Ferber Ally T, Greenwald Brian D
Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA.
Department of Physical Medicine and Rehabilitation, JFK Johnson Rehabilitation Institute at Hackensack Meridian Health, Edison, NJ 08820, USA.
Brain Sci. 2025 May 26;15(6):572. doi: 10.3390/brainsci15060572.
This narrative review explores psilocybin's potential use as a therapeutic agent in patients with traumatic brain injury (TBI). We engaged in a search of PubMed, ScienceDirect, and Cochrane's databases for information on the effects of psilocybin. We also reviewed articles where psilocybin was used in patients with TBI. Articles from 2000-2025 were included. A total of 29 articles met our initial inclusion criteria. Additionally, 13 articles were obtained from reference lists and 3 more articles on the legality of psilocybin from public websites. Assisted psilocybin use may have benefits in TBI by reducing inflammation, promoting neuroplasticity and neuroregeneration, and alleviating associated mood disorders. Positive findings in related fields, like treatment for depression and addiction, highlight the necessity for more extensive clinical trials on psilocybin's role in TBI recovery.
本叙述性综述探讨了裸盖菇素在创伤性脑损伤(TBI)患者中作为治疗药物的潜在用途。我们在PubMed、ScienceDirect和Cochrane数据库中搜索了有关裸盖菇素作用的信息。我们还查阅了使用裸盖菇素治疗TBI患者的文章。纳入了2000年至2025年的文章。共有29篇文章符合我们的初始纳入标准。此外,从参考文献列表中获取了13篇文章,并从公共网站上获取了另外3篇关于裸盖菇素合法性的文章。辅助使用裸盖菇素可能通过减轻炎症、促进神经可塑性和神经再生以及缓解相关情绪障碍而对TBI有益。相关领域(如抑郁症和成瘾治疗)的积极研究结果凸显了对裸盖菇素在TBI恢复中作用进行更广泛临床试验的必要性。
Cochrane Database Syst Rev. 2016-7-1
Neurosci Biobehav Rev. 2025-8
J Psychoactive Drugs. 2024
Cochrane Database Syst Rev. 2017-12-29
Cochrane Database Syst Rev. 2021-10-12
Cochrane Database Syst Rev. 2022-11-14
Cochrane Database Syst Rev. 2016-4-4
Microb Biotechnol. 2025-4
Eur Neuropsychopharmacol. 2024-8
JAMA Netw Open. 2024-4-1
Life (Basel). 2023-12-15
J Psychopharmacol. 2023-9